Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMYRE: plitidepsin + dexamethasone vs dexamethasone in relapsed/refractory multiple myeloma
NL-OMON39027Phase 3Active, not recruiting
- Sponsor
- PharmaMar
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Plitidepsin + dexamethasone with Dexamethasone alone (2 arms). Primary endpoints: Progression-free survival, Adverse events and 5 more. Started Dec 2010; status: active, not recruiting.
02
Drugs
plitidepsindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON39027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39027.